These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9659 related articles for article (PubMed ID: 1829394)

  • 1. Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.
    Mansfield PF; Rosenblum MG; Murray JL; Itoh K
    Cancer Immunol Immunother; 1991; 33(4):247-54. PubMed ID: 1829394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of HC antibody in autologous tumor-specific cytotoxicity by human melanoma tumor-infiltrating lymphocytes.
    Mansfield PF; Salmeron MA; Rosenblum MG; Itoh K
    Int J Cancer; 1991 Sep; 49(3):356-61. PubMed ID: 1917133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine production by human melanoma tumor-infiltrating lymphocytes.
    Salmeron MA; Morita T; Seki H; Platsoucas CD; Itoh K
    Cancer Immunol Immunother; 1992; 35(3):211-7. PubMed ID: 1386286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
    Itoh K; Platsoucas CD; Balch CM
    J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of in vitro tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies.
    Reid I; Lundy J; Donohue JH
    J Immunol; 1992 Apr; 148(8):2630-5. PubMed ID: 1532818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
    Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
    J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
    Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA
    J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating CD3- NK cells are more effective than CD3+ T cells in killing autologous melanoma cells.
    Azogui O; Avril MF; Margulis A; Guillard M; Caillou B; Prade M
    J Invest Dermatol; 1991 Sep; 97(3):425-9. PubMed ID: 1831465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytological characteristics of human glioma-infiltrating lymphocytes stimulated with recombinant interleukin 2 and an anti-CD3 antibody.
    Kikuchi T; Watanabe M; Ohno T
    Jpn J Cancer Res; 1991 Mar; 82(3):339-45. PubMed ID: 1827092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth and autologous tumor lysis by tumor-infiltrating lymphocytes from metastatic melanoma expanded in interleukin-2 or interleukin-2 plus interleukin-4.
    Lindgren CG; Thompson JA; Higuchi CM; Fefer A
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):322-8. PubMed ID: 8280715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of suppressor cells to T- and B-cell proliferative responses and immunoglobulin production by monoclonal antibodies recognizing the CD3 T-cell differentiation antigen.
    Kunicka JE; Platsoucas CD
    Cell Immunol; 1988 Oct; 116(1):195-215. PubMed ID: 2901914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
    Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of uncultured human melanoma cells in the proliferation of autologous tumor-specific cytotoxic T lymphocytes.
    Salmeron MA; Balch CM; Ross MI; Itoh K
    Cell Immunol; 1992 Aug; 143(1):228-37. PubMed ID: 1623565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI; Nelson H; Thibault C
    J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.
    Nishimura T; Nakamura Y; Takeuchi Y; Gao XH; Tokuda Y; Okumura K; Habu S
    Jpn J Cancer Res; 1991 Nov; 82(11):1207-10. PubMed ID: 1836455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of MC-38 adenocarcinoma tumor-specific tumor infiltrating lymphocytes by murine anti-CD3 antibody and recombinant interleukin-2.
    Lafreniere R; Borkenhagen K; Bryant LD
    Mol Biother; 1991 Mar; 3(1):26-33. PubMed ID: 1829898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood and tumor infiltrating lymphocytes in non-small cell lung cancer: analysis at the population and clonal level.
    Viale M; Ferrini S; Serrano S; Serrano D; Ardizzoni A; Nicolin A
    Tumori; 1990 Oct; 76(5):488-94. PubMed ID: 2175060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy.
    Itoh K; Hayakawa K; Salmeron MA; Legha SS; Murray JL; Talpaz M; Balch CM; Parkinson DR; Lee K; Zukiwski AA
    Cancer Immunol Immunother; 1991; 33(4):238-46. PubMed ID: 2059968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 483.